Interleukin-6: A New Therapeutic Target in Scleroderma PDF Print E-mail
Sunday, 12 May 2013 19:15
Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells, except lymphocytes and hepatocytes, express the functional membrane IL-6 receptor thus reducing the number of IL-6-responsive cells. Transsignalling, the shedding of the membrane-bound form of the IL-6 receptor into the local microenvironment, greatly increases the range of cells that can respond. IL-6 has been demonstrated to have a pivotal role in the pathogenesis of rheumatoid arthritis, Castleman’s disease and Crohn’s disease exemplified by the use of an anti-IL-6 biological therapy.

However, IL-6 is also associated with the autoimmune disease systemic sclerosis (SSc) and has been shown to be directly fibrotic. Elevated levels of IL-6 are found in SSc patients and this correlates with skin thickness, suggesting a causal effect. This review focuses on the role of IL-6 in SSc, a chronic autoimmune disease with fibrosis. In particular, we will examine the evidence base of the role of IL-6 in fibrosis in this condition, especially the downstream effector pathways. We will then argue why molecular targeting of IL-6 is a promising therapeutic target in this fibrosing disease.

To read the full article, click on and download from the link provided below.

 
More articles :

» When Our Antibodies Turn On Us

More than 32 million Americans harbor potentially toxic proteins that can attack body tissues and lead to autoimmune diseases such as Lupus and , according to a new study. This is the first accurate estimate of the frequency of the proteins, called...

» Knowing When to Get a Second Doctor’s Opinion

Knowing When to Get a Second Doctor’s Opinion. You won’t often hear doctors say it, but medicine is not an exact science. Not all diseases are clear-cut and easy to diagnose. Not all patients with the same condition will experience the same...

» Morphea Scleroderma

Morphea, is one of two types of localized , and a disorder characterized by excessive deposits leading to thickening of the dermis, subcutaneous tissues, or both. The cause of Scleroderma is unknown. It is important to remember that it is not...

» Facing Life's Challenges

At 57 years of age Anne Wersching doesn’t have a single wrinkle on her face.Sitting in her lounge room in Bayswater North, Ms Wersching looks well, save for a few red marks on her cheeks.But Ms Wersching has a little-known disease called...

» The Scleroderma Foundation Teams Up with Traitwise

The has teamed up with Austin, TX company, Incorporated, to launch a unique survey to poll thousands of patients and their caregivers. Data from the survey will be shared with researchers nationally and internationally in an effort to improve...

» Researchers Gain Deeper Insights Into Causes And New Treatment Strategies For Scleroderma

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of , showing that a critical culprit is a defect in the way certain cells communicate with their structural...